Mikrogen Diagnostik recomWell Chlamydia trachomatis IgA ELISA Kit (6905)

$462.00

Host	Quantity	Applications	Species Reactivity	Data Sheet
	96 Tests	ELISA	Chlamydia trachomatis

SKU: 6905 Categories: Infectious Disease Test Kits and Positive Controls, MIKROGEN Products

Overview

Product Name Mikrogen Diagnostik recomWell Chlamydia trachomatis IgA ELISA Kit (6905)

Description Enzyme immunoassay with antigens produced by recombinant techniques for the detection of IgG and IgA antibodies against Chlamydia trachomatis in serum and plasma

Product is intended for research use.

Target Human Chlamydia trachomatis IgA

Species Reactivity Chlamydia trachomatis

Assay Type Indirect ELISA

Applications ELISA

Properties

Background Chlamydia trachomatis is one of the most common causes of sexually trans-mitted diseases (STD) in industrial nations. According to estimations of the US Center for Disease Control and Prevention (CDC), more than 700 million peo-ple are infected with Chlamydia trachomatis worldwide. The annual incidence is 50 million cases, in Germany approximately 1.15 million.19 different serotypes of Chlamydia trachomatis are known, causing different ranges of disease. Serotypes A-C cause trachoma, a chronic inï¬‚ammation of the eye (keratoconjunctivitis), which is the most common cause of prevent-able blindness worldwide (distribution: Africa, Asia, Australia, Oceania). Se-rotypes L1-L3 are prevalent in tropical regions and are sexually transmitted. The clinical picture (lymphogranuloma venereum) shows heavily inï¬‚amed genital ulcers with partially purulent swollen lymph nodes. Similarly, sexually transmitted in the northern hemisphere (industrial nations) are the serotypes D-K which may cause sterility or arthritis after infections of the genitals or the joints both in women and in men. Perinatal transmission of the pathogen from the infected mother to the newborn results in the so-called neonatal conjunc-tivitis or neonatal pneumonia.The primary infection often persists in an uncharacteristic and oligosympto-matic clinical course, thus supporting proliferation and spread of the infection. Since a primary infection apparently does not induce complete immunity, rein-fections are not a rare event. Accordingly, the therapy is often a tedious proc-ess and will only be successful if antibiotics, which reach a high intracellular active ingredient level, are used. According to the course of Chlamydia infec-tion an antibiotic therapy of the respective sexual partner(s) is recommended to avoid reinfections and increase the success of therapy.

Sample Type Serum, plasma, whole blood

Assay Resolution See Figure

Components

10X Wash Buffer	100 mL
Dilution Buffer	125 mL
TMB Substrate	12 mL
Stop Slution	12 mL
Instuctions for Use	1 Each
Evaluation Form	1 Each
Microplate Sealing Tape	2 Each
Microtiter Plate	12 x 8 Wells
Positive Control	450 uL
Cut-Off Control	450 uL
Negative Control	450 uL
Anti-Human IgA Conjugate	500 uL